New Horizon Health (FRA:6YZ) 1-Year Sharpe Ratio: -90.49 (As of Sep. 22, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:6YZ New Horizon Health Ltd FRA:6YZ
35 GF Score
Price €1.62
View Full Analysis

What is New Horizon Health 1-Year Sharpe Ratio?

New Horizon Health FRA:6YZ 35 1-Year Sharpe Ratio is -90.49 as of Sep. 22, 2026. GuruFocus rates FRA:6YZ with a GF Score™ of 35/100.

The 1-Year Sharpe Ratio measures the additional return that an investor receives per unit of increase in risk over the past year. As of today (2026-09-22), New Horizon Health's 1-Year Sharpe Ratio is -90.49.

New Horizon Health  (FRA:6YZ) 1-Year Sharpe Ratio Explanation

The 1-Year Sharpe Ratio inidicates the risk-adjusted return of an investment over the past year. It is calculated as the annualized result of the average monthly excess return divided by its standard deviation over the past year. The monthly excess return is the monthly investment return minus the monthly risk-free rate (typically the 10-year Treasury Constant Maturity Rate). If the risk-free rate for a specific region is not available, U.S. data is used by default.

The greater a portfolio's Sharpe Ratio, the better its risk-adjusted performance. A negative Sharpe Ratio means the risk-free rate is greater than the portfolio’s historical or projected return, or else the portfolio's return is expected to be negative.

New Horizon Health 1-Year Sharpe Ratio Related Terms

FRA:6YZ vs ABT, SYK, MDT: 1-Year Sharpe Ratio Comparison

For the Medical Devices subindustry, New Horizon Health's 1-Year Sharpe Ratio, along with its competitors' market caps and 1-Year Sharpe Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

New Horizon Health 1-Year Sharpe Ratio vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, New Horizon Health's 1-Year Sharpe Ratio distribution charts can be found below:

* The bar in red indicates where New Horizon Health's 1-Year Sharpe Ratio falls into.


FRA:6YZ
35GF Score
New Horizon Health Ltd FRA:6YZ
1-Year Sharpe Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

New Horizon Health 1-Year Sharpe Ratio Calculation

The 1-Year Sharpe Ratio measures the performance of an investment such as a stock or portfolio compared to a risk-free asset. A stock / portfolio's 1-Year Sharpe Ratio can be calculated by dividing the difference between the one-year returns of the investment and the risk-free rate, by the standard deviation of the investment returns over one year.

Frequently Asked Questions Learn more about 1-Year Sharpe Ratio →
What does a 1-Year Sharpe Ratio of -90.49 mean?
New Horizon Health (FRA:6YZ) has a 1-Year Sharpe Ratio of -90.49 as of Sep. 22, 2026. 1-Year Sharpe Ratio measures the additional return that an investor receives per unit of increase in risk. View historical data for New Horizon Health and its competitors.
Is New Horizon Health's 1-Year Sharpe Ratio too high?
New Horizon Health's current 1-Year Sharpe Ratio is -90.49. Overall, New Horizon Health has a GF Score™ of 35/100, reflecting its overall financial health beyond just this single metric.
How does New Horizon Health's 1-Year Sharpe Ratio compare to ABT and SYK?
New Horizon Health's 1-Year Sharpe Ratio of -90.49 can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 1-Year Sharpe Ratio for a Medical Devices & Instruments company?
A good 1-Year Sharpe Ratio depends on the Medical Devices & Instruments industry context. However, 1-Year Sharpe Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 1-Year Sharpe Ratio mean?
A high 1-Year Sharpe Ratio can signal that a stock is expensive relative to its fundamentals. 1-Year Sharpe Ratio measures the additional return that an investor receives per unit of increase in risk. View historical data for New Horizon Health and its competitors. New Horizon Health's current 1-Year Sharpe Ratio is -90.49. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is New Horizon Health stock overvalued right now?
New Horizon Health (FRA:6YZ) has a current 1-Year Sharpe Ratio of -90.49. The current 1-Year Sharpe Ratio is -90.49. New Horizon Health's overall GF Score™ is 35/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 1-Year Sharpe Ratio calculated?
1-Year Sharpe Ratio is calculated from a company's financial statements. For New Horizon Health (FRA:6YZ), the current 1-Year Sharpe Ratio is -90.49 as of Sep. 22, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

New Horizon Health Business Description

Address 400 Jiang’er Road, 13th Floor, T1 Building, Binjiang District, Zhejiang, Hangzhou, CHN, 310052
New Horizon Health Ltd is a Chinese healthcare company focused on early cancer screening and in-home testing. Its core product, ColoClear, is a non-invasive stool DNA test for colorectal cancer screening, while Pupu Tube is a fecal immunochemical testing product for at-home use. The company also develops and markets products and product candidates targeting other cancers and health conditions, with an emphasis on colorectal cancer detection. It sells primarily to individual consumers in China through hospitals, clinics, physical examination centers, and online and direct-to-consumer channels. Revenue is generated mainly from sales of its screening test kits, with ColoClear and Pupu Tube accounting for the largest share. The company operates largely in the Chinese market, where it promotes cancer prevention through accessible, at-home screening and early detection.
35GF Score

Get the complete analysis for FRA:6YZ

1-Year Sharpe Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€1.62
Price